All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 EGFR mutation Ex19del EGFR mutation L858R Gender, female Gender, male metastasis (liver ) smoker (current or former) smoker (never) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), ... vs. ..., meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias progression or deaths (PFS)detailed results RELAY, 2017 0.59 [0.46; 0.76]
0.59 [0.46 ; 0.76 ] RELAY, 2017 1 0% 449 NA not evaluable DCRdetailed results RELAY, 2017 0.90 [0.37; 2.17]
0.90 [0.37 ; 2.17 ] RELAY, 2017 1 0% 449 NA not evaluable DORdetailed results RELAY, 2017 0.45 [0.28; 0.72]
0.45 [0.28 ; 0.72 ] RELAY, 2017 1 0% 339 NA not evaluable objective responses (ORR)detailed results RELAY, 2017 1.09 [0.71; 1.68]
1.09 [0.71 ; 1.68 ] RELAY, 2017 1 0% 449 NA not evaluable AE (any grade)detailed results RELAY, 2017 0.98 [0.02; 49.72]
0.98 [0.02 ; 49.72 ] RELAY, 2017 1 0% 446 NA not evaluable AE (grade 3-4)detailed results RELAY, 2017 1.97 [1.34; 2.90]
1.97 [1.34 ; 2.90 ] RELAY, 2017 1 0% 446 NA not evaluable AE leading to death (grade 5)detailed results RELAY, 2017 4.10 [0.18; 91.44]
4.10 [0.18 ; 91.44 ] RELAY, 2017 1 0% 446 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results RELAY, 2017 1.22 [0.68; 2.17]
1.22 [0.68 ; 2.17 ] RELAY, 2017 1 0% 446 NA not evaluable SAE (any grade)detailed results RELAY, 2017 1.58 [1.02; 2.43]
1.58 [1.02 ; 2.43 ] RELAY, 2017 1 0% 446 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 12:27 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 1028